Drug Sponsors

Elan sells remaining stake in Alkermes

Friday, February 1, 2013 01:43 PM

Following the close of trading today, Elan’s wholly-owned subsidiary, Elan Science Three, agreed to sell, on customary terms, all of its remaining 7,750,000 ordinary shares of Alkermes through Jefferies & Company pursuant to Rule 144 under the U.S. Securities Act of 1933. The sale is expected to close on February 6, 2013.

More... »

Ocular Therapeutix closes $23.8M Series D extension

Wednesday, January 30, 2013 10:39 AM

Ocular Therapeutix, a privately held company based in Bedford, Mass.,recently closed a Series D extension round of financing totaling $23.8 million.

More... »

Boston Scientific expands restructuring program

Wednesday, January 30, 2013 10:11 AM

Boston Scientific, a medical device company based in Natick, Mass., has announced an expansion of its 2011 restructuring program intended to build on the progress made under that program to strengthen its operational effectiveness and efficiencies and support new growth investments, which is expected to increase shareholder value. 

More... »

Celsion, Zhejiang Hisun enter into tech development agreement for ThermoDox

Monday, January 28, 2013 10:24 AM

Celsion, an oncology drug development company, and Zhejiang Hisun Pharmaceutical, a Chinese pharmaceutical company, have entered into a technology development agreement for ThermoDox for the Greater China territory. 

More... »

Salk Institute awarded $42M from Helmsley Charitable Trust

Monday, January 28, 2013 09:55 AM

The Salk Institute for Biological Studies, a San Diego-based institute focused both on discovery and on mentoring future generations of researchers, has received a $42 million gift from The Leona M. and Harry B. Helmsley Charitable Trust to establish the Helmsley Center for Genomic Medicine (HCGM).

More... »

DelMar Inc. acquires shares of DelMar Ltd.

Friday, January 25, 2013 01:43 PM

DelMar Pharmaceuticals, Inc., a Canadian pharmaceutical company that develops drug candidates targeting orphan cancer indications, has completed the acquisition of all of the outstanding shares of DelMar Pharmaceuticals Ltd., a clinical and commercial stage drug development company with a focus on the treatment of cancer. 

More... »

Domain grants Prexton exclusive license and development of mGluR4 PAMs for Parkinson’s

Friday, January 25, 2013 11:01 AM

Domain Therapeutics, a French biopharmaceutical company, has granted Switzerland–based Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease.

More... »

Ipsen, Inspiration enter into asset purchase agreement with Baxter on OBI-1

Friday, January 25, 2013 10:32 AM

Ipsen, a global specialty-driven pharmaceutical company, and Inspiration Biopharmaceuticals, a biopharmaceutical company focused on hemophilia, have entered into an Asset Purchase Agreement (APA) whereby healthcare company Baxter International will acquire worldwide rights to OBI-1, a recombinant porcine factor VIII (rpFVIII) in development for congenital hemophilia A with inhibitors and acquired hemophilia A, and Ipsen's industrial facility in Milford, Mass.

More... »

Allergan to acquire MAP Pharmaceuticals

Wednesday, January 23, 2013 12:18 PM

Allergan and MAP Pharmaceuticals, both based in California, have jointly announced a definitive merger agreement whereby Allergan will acquire 100% of MAP Pharmaceuticals shares for $25 per share. MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies in neurology, including Levadex, an orally inhaled drug for the potential acute treatment of migraine in adults which is currently is under review with the FDA.

More... »

Recordati finalizes acquisition of portfolio from Lundbeck

Wednesday, January 23, 2013 11:25 AM

Recordati, a specialty pharmaceutical group based in Italy, has successfully concluded the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the U.S. from pharmaceutical company Lundbeck. The value of the transaction is of $100 million, of which $80 million were paid at the closing.

More... »